These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 28980886)

  • 21. Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.
    Park S; Yoon JH; Sohn J; Park HS; Moon HJ; Kim MJ; Kim EK; Kim SI; Park BW
    PLoS One; 2016; 11(2):e0149347. PubMed ID: 26866475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
    Wu J; Gong G; Cui Y; Li R
    J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
    Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
    Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
    Park SH; Moon WK; Cho N; Song IC; Chang JM; Park IA; Han W; Noh DY
    Radiology; 2010 Oct; 257(1):56-63. PubMed ID: 20851939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
    Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
    Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.
    Zhang F; Huang M; Zhou H; Chen K; Jin J; Wu Y; Ying L; Ding X; Su D; Zou D
    Ann Surg Oncol; 2019 Nov; 26(12):3912-3919. PubMed ID: 31359285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
    Matsuda N; Kida K; Ohde S; Suzuki K; Yamauchi H; Nakamura S; Tsunoda H
    Breast Cancer; 2018 Jan; 25(1):43-49. PubMed ID: 28536943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
    Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
    Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy.
    Dongfeng H; Daqing M; Erhu J
    Clin Breast Cancer; 2012 Apr; 12(2):94-101. PubMed ID: 22169574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM; Gatsonis CA; Rosen MA; Lehman CD; Newitt DC; Partridge SC; Bernreuter WK; Pisano ED; Morris EA; Weatherall PT; Polin SM; Newstead GM; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2016 Apr; 279(1):44-55. PubMed ID: 26624971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy.
    Park MJ; Kim SH; Lee SJ; Jang KM; Rhim H
    Radiology; 2011 Sep; 260(3):771-80. PubMed ID: 21846762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Texture analysis based on contrast-enhanced MRI can predict treatment response to neoadjuvant chemotherapy of breast cancer].
    Sun SH; Zhou CW; Zhao LY; Zhang RZ; Ouyang H
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):344-349. PubMed ID: 28535650
    [No Abstract]   [Full Text] [Related]  

  • 34. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
    Baek HM; Chen JH; Nie K; Yu HJ; Bahri S; Mehta RS; Nalcioglu O; Su MY
    Radiology; 2009 Jun; 251(3):653-62. PubMed ID: 19276320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
    Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
    Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
    Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
    Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
    Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
    Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response.
    Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A
    Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.